Hussein A. Tawbi

2003–2025 年に発表

別表記
Hussein A Tawbi
121
論文数
26,262
被引用数
60
h 指数
111
i10 指数

被引用数

Hussein A. Tawbi の年別被引用数2001 年: 被引用 1 件2003 年: 被引用 1 件2005 年: 被引用 3 件2006 年: 被引用 1 件2007 年: 被引用 4 件2008 年: 被引用 3 件2009 年: 被引用 9 件2010 年: 被引用 6 件2011 年: 被引用 1 件2012 年: 被引用 12 件2013 年: 被引用 36 件2014 年: 被引用 42 件2015 年: 被引用 58 件2016 年: 被引用 85 件2017 年: 被引用 127 件2018 年: 被引用 259 件2019 年: 被引用 920 件2020 年: 被引用 1,440 件2021 年: 被引用 1,538 件2022 年: 被引用 1,726 件2023 年: 被引用 1,644 件2024 年: 被引用 2,378 件2025 年: 被引用 1,400 件2026 年: 被引用 38 件2002 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,855 件、この内訳の 25.9%中国: 引用元論文 2,393 件、この内訳の 16.1%イタリア: 引用元論文 846 件、この内訳の 5.7%フランス: 引用元論文 735 件、この内訳の 4.9%ドイツ: 引用元論文 732 件、この内訳の 4.9%イギリス: 引用元論文 703 件、この内訳の 4.7%オーストラリア: 引用元論文 494 件、この内訳の 3.3%カナダ: 引用元論文 476 件、この内訳の 3.2%オランダ: 引用元論文 449 件、この内訳の 3%スペイン: 引用元論文 415 件、この内訳の 2.8%日本: 引用元論文 408 件、この内訳の 2.7%スイス: 引用元論文 361 件、この内訳の 2.4%
0%25.9%その他 20.4%

分野

  • Medicine59.7%
  • Biochemistry, Genetics and Molecular Biology27.6%
  • Immunology and Microbiology9.2%
  • Engineering0.8%
  • Neuroscience0.8%
  • Computer Science0.3%
  • その他1.6%

トピック

  • Cancer Immunotherapy and Biomarkers15.5%
  • Immunotherapy and Immune Responses6%
  • Gut microbiota and health5.9%
  • CAR-T cell therapy research5.1%
  • Immune Cell Function and Interaction3.6%
  • Melanoma and MAPK Pathways2.7%
  • その他61.2%

共著者

全論文

検索で開く
  1. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pablo C. Okhuysen, V. Behrana Jensen, Alton G. Swennes, Florencia McAllister, Erick Riquelme, Yexi Zhang, Emmanuelle Le Chatelier, Laurence Zitvogel, Nicolas Pons, Jacob L. Austin-Breneman, Lauren E. Haydu, Elizabeth M. Burton, Julie M. Gardner, Elizabeth Sirmans, Jiemiao Hu, Alexander J. Lazar, Takahiro Tsujikawa, Adi Diab, Hussein A. Tawbi, Isabella C. Glitza, Wen-Jen Hwu, Sapna P. Patel, Scott E. Woodman, Rodabe N. Amaria, Michael A. Davies, Jeffrey E. Gershenwald, Patrick Hwu, J. E. Lee, J. Zhang, Lisa M. Coussens, Zachary A. Cooper, P. Andrew Futreal, Carrie R. Daniel, Nadim J. Ajami, Joseph F. Petrosino, Michael T. Tetzlaff, Padmanee Sharma, James P. Allison, Robert R. Jenq, Jennifer A. Wargo - Science 2017 被引用: 4,788

  2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 1,759

  3. B cells are associated with survival and immunotherapy response in sarcoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2020 被引用: 1,970

  4. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed A. Jamal, Erez N. Baruch, Eva Pérez‐Guijarro, Chi‐Ping Day, Glenn Merlino, Barbara Pazdrak, Brooke S. Lochmann, Robert Szczepaniak‐Sloane, Reetakshi Arora, Jaime Anderson, Chrystia M. Zobniw, Eliza Posada, Elizabeth Sirmans, Julie M. Simon, Lauren E. Haydu, Elizabeth M. Burton, Linghua Wang, Minghao Dang, Karen Clise-Dwyer, Sarah Schneider, Thomas Chapman, Nana-Ama A.S. Anang, Sheila Duncan, Joseph Toker, Jared Malke, Isabella C. Glitza, Rodabe N. Amaria, Hussein A. Tawbi, Adi Diab, Michael K. Wong, Sapna P. Patel, Scott E. Woodman, Michael A. Davies, Merrick I. Ross, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, V. Behrana Jensen, Yardena Samuels, Ravid Straussman, Nadim J. Ajami, Kelly C. Nelson, Luigi Nezi, Joseph F. Petrosino, P. Andrew Futreal, Alexander J. Lazar, Jianhua Hu, Robert R. Jenq, Michael T. Tetzlaff, Yan Yan, Wendy S. Garrett, Curtis Huttenhower, Padmanee Sharma, Stephanie S. Watowich, James P. Allison, Lorenzo Cohen, Giorgio Trinchieri, Carrie R. Daniel, Jennifer A. Wargo - Science 2021 被引用: 932

  5. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 1,423

  6. Neoadjuvant relatlimab and nivolumab in resectable melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sapna P. Patel, Adi Diab, Anthony Lucci, Víctor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte E. Ariyan, Hussein A. Tawbi - Nature 2022 被引用: 332

  7. Development of Immunotherapy Combination Strategies in Cancer

    著者: , , , , , - Cancer Discovery 2021 被引用: 320

  8. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,321

  9. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Khalida Wani, Alexander J. Lazar, Michael T. Tetzlaff, Courtney W. Hudgens, Margaret K. Callahan, Matthew Adamow, Michael A. Postow, Charlotte E. Ariyan, Pierre-Olivier Gaudreau, Luigi Nezi, Didier Raoult, Catalin Mihalcioiu, Arielle Elkrief, Rossanna C. Pezo, Lauren E. Haydu, Julie M. Simon, Hussein A. Tawbi, Jennifer L. McQuade, Patrick Hwu, Wen-Jen Hwu, Rodabe N. Amaria, Elizabeth M. Burton, Scott E. Woodman, Stephanie S. Watowich, Adi Diab, Sapna P. Patel, Isabella C. Glitza, Michael K.K. Wong, Li Zhao, Jianhua Zhang, Nadim J. Ajami, Joseph F. Petrosino, Robert R. Jenq, Michael A. Davies, Jeffrey E. Gershenwald, P. Andrew Futreal, Padmanee Sharma, James P. Allison, Bertrand Routy, Laurence Zitvogel, Jennifer A. Wargo - Nature Medicine 2021 被引用: 415

  10. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Liberty Posada, Lauren E. Haydu, Linghua Wang, Shaojun Zhang, Alexander J. Lazar, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Alexandre Reuben, Miles C. Andrews, Christine N. Spencer, Víctor G. Prieto, Padmanee Sharma, James P. Allison, Michael T. Tetzlaff, Jennifer A. Wargo - Nature Medicine 2018 被引用: 826

  11. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

    著者: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2021 被引用: 430

  12. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 322

  13. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 被引用: 280

  14. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott E. Woodman, Rodabe N. Amaria, Víctor G. Prieto, Jianhua Hu, Padmanee Sharma, James P. Allison, Lynda Chin, Jianhua Zhang, Jennifer A. Wargo, P. Andrew Futreal - Science Translational Medicine 2017 被引用: 920

  15. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 155

  16. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

    著者: , , , , , , , , , , , , , , , , , , , - NEJM Evidence 2023 被引用: 124

  17. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jianjun Zhang, Sheri L. Holmen, Michael T. Tetzlaff, Michael A. Davies - Cancer Discovery 2019 被引用: 347

  18. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2022 被引用: 192

  19. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 163

  20. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - 2022 被引用: 146

  21. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 834

  22. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

    著者: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 被引用: 241

  23. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

    著者: , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2016 被引用: 514

  24. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, P. Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva - Nature Communications 2022 被引用: 116